Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study

Bone. 2021 Nov:152:116065. doi: 10.1016/j.bone.2021.116065. Epub 2021 Jun 19.

Abstract

Background: Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) are gut hormones secreted in response to food ingestion, and they have been suggested to regulate bone turnover. In humans, exogenous GIP and GLP-2 acutely inhibit bone resorption as measured by circulating levels of carboxy-terminal type 1 collagen crosslinks (CTX).

Objective: The objective was to study the individual and combined acute effects of GIP and GLP-2 on bone turnover in postmenopausal women during nighttime - a period of increased bone resorption.

Methods: Using a randomized, placebo-controlled, double-blinded, crossover design, each participant (n = 9) received on four separate study days: GIP, GLP-2, GIP + GLP-2, and placebo (saline) as subcutaneous injections at bedtime. Main outcomes were levels of CTX and procollagen type 1 N-terminal propeptide (P1NP).

Results: Compared with placebo, GIP and GLP-2 alone significantly inhibited bone resorption (measured by CTX). GIP rapidly reduced CTX levels in the period from 45 to 120 min after injection, while GLP-2 had a more delayed effect with reduced CTX levels in the period from 120 to 240 min after injection. Combining GIP and GLP-2 showed complementary effects resulting in a sustained inhibition of CTX with reduced levels from 45 to 240 min after injection. Furthermore, GIP acutely increased bone formation (measured by P1NP).

Conclusion: Both GIP and GLP-2 reduced CTX during the night and had complementary effects when combined.

Keywords: Bone turnover; CTX; Glucagon-like peptide-2 (GLP-2); Glucose-dependent insulinotropic polypeptide (GIP); Gut-bone axis; P1NP.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Glucose
  • Bone Remodeling
  • Bone Resorption* / drug therapy
  • Female
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptide 2*
  • Humans
  • Peptide Fragments
  • Postmenopause

Substances

  • Blood Glucose
  • Glucagon-Like Peptide 2
  • Peptide Fragments
  • Gastric Inhibitory Polypeptide